Lundbeck expands its commercial opportunities in Canada and Latin America

On February 8, 2011 Lundbeck reported that it has been granted commercial rights to several Cephalon products in Canada and Latin America (Press release , FEB 8, 2011, View Source [SID:1234500347]). As part of the agreement, Lundbeck will register and commercialize several key products which are currently available in the US and/or Europe on behalf of Cephalon. Key products in the agreement include Fentora() (fentanyl buccal tablet) [C-II], Provigil(), Treanda(), Trisenox() (arsenic trioxide) injection, Myocet( )(liposomal- doxorubicin) and Nuvigil().

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Also included in the deal is the leading Cephalon oncology product Treanda() which is to be commercialized by Lundbeck in Canada. Treanda() will add significantly to revenue and earnings in Lundbeck’s Canadian business. The new oncology franchise in Canada will be complemented by Trisenox() and the pain product, Fentora(). Treanda() has proven clinical activity in the treatment of hematological malignancies, including those refractory to conventional anti- cancer agents.

In 2008, the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) recognized Treanda() as one of the major advances in cancer treatment. In 2009, Cephalon realized total revenue of USD 222 million on the product and in the first nine months of 2010 revenue reached USD 285 million in the U.S. Treanda( )is expected to be filed during 2011 in Canada and Lundbeck will establish a dedicated oncology sales organization in Latin America and Canada in order to achieve the full potential of the oncology portfolio.
The financial terms of the agreement have not been disclosed, but Lundbeck is to pay double-digit royalties on sales which will be the main overall revenue stream for Cephalon from these products in these territories.